ID   CSPG2_HUMAN             Reviewed;        3396 AA.
AC   P13611; P20754; Q13010; Q13189; Q15123; Q9UCL9; Q9UNW5;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 3.
DT   03-AUG-2022, entry version 242.
DE   RecName: Full=Versican core protein;
DE   AltName: Full=Chondroitin sulfate proteoglycan core protein 2;
DE            Short=Chondroitin sulfate proteoglycan 2;
DE   AltName: Full=Glial hyaluronate-binding protein;
DE            Short=GHAP;
DE   AltName: Full=Large fibroblast proteoglycan;
DE   AltName: Full=PG-M;
DE   Flags: Precursor;
GN   Name=VCAN; Synonyms=CSPG2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM V1), AND SUBCELLULAR LOCATION.
RC   TISSUE=Placenta;
RX   PubMed=2583089; DOI=10.1002/j.1460-2075.1989.tb08447.x;
RA   Zimmermann D.R., Ruoslahti E.;
RT   "Multiple domains of the large fibroblast proteoglycan, versican.";
RL   EMBO J. 8:2975-2981(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM V2).
RC   TISSUE=Glial tumor;
RX   PubMed=7806529; DOI=10.1016/s0021-9258(20)30089-2;
RA   Dours-Zimmermann M.T., Zimmermann D.R.;
RT   "A novel glycosaminoglycan attachment domain identified in two alternative
RT   splice variants of human versican.";
RL   J. Biol. Chem. 269:32992-32998(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM V0).
RX   PubMed=7528742; DOI=10.1016/s0021-9258(20)30090-9;
RA   Naso M.F., Zimmermann D.R., Iozzo R.V.;
RT   "Characterization of the complete genomic structure of the human versican
RT   gene and functional analysis of its promoter.";
RL   J. Biol. Chem. 269:32999-33008(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM V3).
RC   TISSUE=Brain;
RX   PubMed=7876137; DOI=10.1074/jbc.270.8.3914;
RA   Zako M., Shinomura T., Ujita M., Ito K., Kimata K.;
RT   "Expression of PG-M(V3), an alternatively spliced form of PG-M without a
RT   chondroitin sulfate attachment in region in mouse and human tissues.";
RL   J. Biol. Chem. 270:3914-3918(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 208-1427; 2081-2372 AND 2897-3233 (ISOFORM
RP   V1), AND DEVELOPMENTAL STAGE.
RX   PubMed=7921538; DOI=10.1016/0945-053x(94)90185-6;
RA   Yao L.Y., Moody C., Schoenherr E., Wight T.N., Sandell L.J.;
RT   "Identification of the proteoglycan versican in aorta and smooth muscle
RT   cells by DNA sequence analysis, in situ hybridization and
RT   immunohistochemistry.";
RL   Matrix Biol. 14:213-225(1994).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 251-347.
RX   PubMed=1478664; DOI=10.1016/s0888-7543(05)80103-x;
RA   Iozzo R.V., Naso M.F., Cannizzaro L.A., Wasmuth J.J., McPherson J.D.;
RT   "Mapping of the versican proteoglycan gene (CSPG2) to the long arm of human
RT   chromosome 5 (5q12-5q14).";
RL   Genomics 14:845-851(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2709-3396.
RC   TISSUE=Lung fibroblast;
RX   PubMed=2820964; DOI=10.1016/s0021-9258(18)45176-9;
RA   Krusius T., Gehlsen K.R., Ruoslahti E.;
RT   "A fibroblast chondroitin sulfate proteoglycan core protein contains
RT   lectin-like and growth factor-like sequences.";
RL   J. Biol. Chem. 262:13120-13125(1987).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3333-3396 (ISOFORM VINT).
RC   TISSUE=Aortic smooth muscle;
RX   PubMed=10397680; DOI=10.1161/01.atv.19.7.1630;
RA   Lemire J.M., Braun K.R., Maurel P., Kaplan E.D., Schwartz S.M., Wight T.N.;
RT   "Versican/PG-M isoforms in vascular smooth muscle cells.";
RL   Arterioscler. Thromb. Vasc. Biol. 19:1630-1639(1999).
RN   [9]
RP   PROTEIN SEQUENCE OF 21-37.
RX   PubMed=1429726; DOI=10.1016/s0021-9258(18)35919-2;
RA   Perides G., Rahemtulla F., Lane W.S., Asher R.A., Bignami A.;
RT   "Isolation of a large aggregating proteoglycan from human brain.";
RL   J. Biol. Chem. 267:23883-23887(1992).
RN   [10]
RP   PROTEIN SEQUENCE OF 24-50; 80-119; 128-155; 167-218; 229-268 AND 277-290.
RC   TISSUE=Brain;
RX   PubMed=2466833; DOI=10.1016/s0021-9258(18)83646-8;
RA   Perides G., Lane W.S., Andrews D., Dahl D., Bignami A.;
RT   "Isolation and partial characterization of a glial hyaluronate-binding
RT   protein.";
RL   J. Biol. Chem. 264:5981-5987(1989).
RN   [11]
RP   PROTEIN SEQUENCE OF 171-210 AND 289-303, AND TISSUE SPECIFICITY.
RX   PubMed=2469524; DOI=10.1016/0361-9230(89)90129-9;
RA   Bignami A., Lane W.S., Andrews D., Dahl D.;
RT   "Structural similarity of hyaluronate binding proteins in brain and
RT   cartilage.";
RL   Brain Res. Bull. 22:67-70(1989).
RN   [12]
RP   TISSUE SPECIFICITY (ISOFORMS V0; V1; V2 AND V3).
RX   PubMed=8627343; DOI=10.1097/00005072-199605000-00005;
RA   Paulus W., Baur I., Dours-Zimmermann M.T., Zimmermann D.R.;
RT   "Differential expression of versican isoforms in brain tumors.";
RL   J. Neuropathol. Exp. Neurol. 55:528-533(1996).
RN   [13]
RP   INVOLVEMENT IN WGVRP.
RX   PubMed=16043844; DOI=10.1167/iovs.05-0057;
RA   Miyamoto T., Inoue H., Sakamoto Y., Kudo E., Naito T., Mikawa T.,
RA   Mikawa Y., Isashiki Y., Osabe D., Shinohara S., Shiota H., Itakura M.;
RT   "Identification of a novel splice site mutation of the CSPG2 gene in a
RT   Japanese family with Wagner syndrome.";
RL   Invest. Ophthalmol. Vis. Sci. 46:2726-2735(2005).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   INVOLVEMENT IN WGVRP, AND PATHOLOGICAL MECHANISM.
RX   PubMed=22739342; DOI=10.1038/ejhg.2012.137;
RA   Kloeckener-Gruissem B., Neidhardt J., Magyar I., Plauchu H., Zech J.C.,
RA   Morle L., Palmer-Smith S.M., Macdonald M.J., Nas V., Fry A.E., Berger W.;
RT   "Novel VCAN mutations and evidence for unbalanced alternative splicing in
RT   the pathogenesis of Wagner syndrome.";
RL   Eur. J. Hum. Genet. 21:352-356(2013).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2116 AND THR-2617, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   PHOSPHORYLATION AT SER-2116.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [18]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=29777959; DOI=10.1016/j.actbio.2018.05.023;
RA   Felemban M., Dorgau B., Hunt N.C., Hallam D., Zerti D., Bauer R., Ding Y.,
RA   Collin J., Steel D., Krasnogor N., Al-Aama J., Lindsay S., Mellough C.,
RA   Lako M.;
RT   "Extracellular matrix component expression in human pluripotent stem cell-
RT   derived retinal organoids recapitulates retinogenesis in vivo and reveals
RT   an important role for IMPG1 and CD44 in the development of photoreceptors
RT   and interphotoreceptor matrix.";
RL   Acta Biomater. 74:207-221(2018).
CC   -!- FUNCTION: May play a role in intercellular signaling and in connecting
CC       cells with the extracellular matrix. May take part in the regulation of
CC       cell motility, growth and differentiation. Binds hyaluronic acid.
CC   -!- SUBUNIT: Interacts with FBLN1. {ECO:0000250}.
CC   -!- INTERACTION:
CC       P13611; P14780: MMP9; NbExp=3; IntAct=EBI-8515977, EBI-1382326;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix {ECO:0000305|PubMed:2583089}. Cell projection, cilium,
CC       photoreceptor outer segment {ECO:0000269|PubMed:29777959}. Secreted,
CC       extracellular space, extracellular matrix, interphotoreceptor matrix
CC       {ECO:0000269|PubMed:29777959}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=V0;
CC         IsoId=P13611-1; Sequence=Displayed;
CC       Name=V1;
CC         IsoId=P13611-2; Sequence=VSP_003082, VSP_003083;
CC       Name=V2;
CC         IsoId=P13611-3; Sequence=VSP_003084;
CC       Name=V3;
CC         IsoId=P13611-4; Sequence=VSP_003082, VSP_003085;
CC       Name=Vint;
CC         IsoId=P13611-5; Sequence=VSP_003086;
CC   -!- TISSUE SPECIFICITY: Expressed in the retina (at protein level)
CC       (PubMed:29777959). Cerebral white matter and plasma (PubMed:2469524).
CC       Isoform V0: Expressed in normal brain, gliomas, medulloblastomas,
CC       schwannomas, neurofibromas, and meningiomas (PubMed:8627343). Isoform
CC       V1: Expressed in normal brain, gliomas, medulloblastomas, schwannomas,
CC       neurofibromas, and meningiomas (PubMed:8627343). Isoform V2: Restricted
CC       to normal brain and gliomas (PubMed:8627343). Isoform V3: Found in all
CC       these tissues except medulloblastomas (PubMed:8627343).
CC       {ECO:0000269|PubMed:2469524, ECO:0000269|PubMed:29777959,
CC       ECO:0000269|PubMed:8627343}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in developing photoreceptors and the
CC       interphotoreceptor matrix between 12 and 17 weeks post conception (at
CC       protein level) (PubMed:29777959). Disappears in aorta after the
CC       cartilage development (PubMed:7921538). {ECO:0000269|PubMed:29777959,
CC       ECO:0000269|PubMed:7921538}.
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       {ECO:0000269|PubMed:26091039}.
CC   -!- PTM: Proteolytically cleaved by ADAMTS5 and ADAMTS15 in the
CC       pericellular matrix surrounding myoblasts, facilitating myoblast
CC       contact and fusion which is required for skeletal muscle development
CC       and regeneration. {ECO:0000250|UniProtKB:Q62059}.
CC   -!- DISEASE: Wagner vitreoretinopathy (WGVRP) [MIM:143200]: A rare
CC       vitreoretinopathy characterized by an optically empty vitreous cavity
CC       with fibrillary condensations and a preretinal avascular membrane.
CC       Other optical features include progressive chorioretinal atrophy,
CC       perivascular sheating, subcapsular cataract and myopia.
CC       {ECO:0000269|PubMed:16043844, ECO:0000269|PubMed:22739342}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry. The pathological mechanism involves a quantitative imbalance of
CC       the normally occurring splice variants (PubMed:22739342).
CC       {ECO:0000269|PubMed:22739342}.
CC   -!- SIMILARITY: Belongs to the aggrecan/versican proteoglycan family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;
CC       Note=Versican;
CC       URL="http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_Ctlect_214";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/VCANID40173ch5q14.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X15998; CAA34128.1; -; mRNA.
DR   EMBL; U16306; AAA65018.1; -; mRNA.
DR   EMBL; U26555; AAA67565.1; -; mRNA.
DR   EMBL; D32039; BAA06801.1; -; mRNA.
DR   EMBL; S52488; AAB24878.1; -; Genomic_DNA.
DR   EMBL; J02814; AAA36437.1; -; mRNA.
DR   EMBL; AF084545; AAD48545.1; -; mRNA.
DR   CCDS; CCDS4060.1; -. [P13611-1]
DR   CCDS; CCDS47242.1; -. [P13611-4]
DR   CCDS; CCDS54875.1; -. [P13611-3]
DR   CCDS; CCDS54876.1; -. [P13611-2]
DR   PIR; S06014; A60979.
DR   RefSeq; NP_001119808.1; NM_001126336.2. [P13611-4]
DR   RefSeq; NP_001157569.1; NM_001164097.1. [P13611-2]
DR   RefSeq; NP_001157570.1; NM_001164098.1. [P13611-3]
DR   RefSeq; NP_004376.2; NM_004385.4. [P13611-1]
DR   SMR; P13611; -.
DR   BioGRID; 107844; 48.
DR   IntAct; P13611; 11.
DR   MINT; P13611; -.
DR   STRING; 9606.ENSP00000265077; -.
DR   DrugBank; DB08818; Hyaluronic acid.
DR   CarbonylDB; P13611; -.
DR   GlyConnect; 1890; 14 N-Linked glycans (9 sites), 1 O-Linked glycan (1 site).
DR   GlyGen; P13611; 193 sites, 13 N-linked glycans (9 sites), 10 O-linked glycans (167 sites).
DR   iPTMnet; P13611; -.
DR   PhosphoSitePlus; P13611; -.
DR   SwissPalm; P13611; -.
DR   BioMuta; VCAN; -.
DR   DMDM; 2506816; -.
DR   EPD; P13611; -.
DR   jPOST; P13611; -.
DR   MassIVE; P13611; -.
DR   MaxQB; P13611; -.
DR   PaxDb; P13611; -.
DR   PeptideAtlas; P13611; -.
DR   PRIDE; P13611; -.
DR   ProteomicsDB; 52938; -. [P13611-1]
DR   ProteomicsDB; 52939; -. [P13611-2]
DR   ProteomicsDB; 52940; -. [P13611-3]
DR   ProteomicsDB; 52941; -. [P13611-4]
DR   ProteomicsDB; 52942; -. [P13611-5]
DR   Antibodypedia; 1346; 323 antibodies from 30 providers.
DR   DNASU; 1462; -.
DR   Ensembl; ENST00000265077.8; ENSP00000265077.3; ENSG00000038427.16. [P13611-1]
DR   Ensembl; ENST00000342785.8; ENSP00000342768.4; ENSG00000038427.16. [P13611-3]
DR   Ensembl; ENST00000343200.9; ENSP00000340062.5; ENSG00000038427.16. [P13611-2]
DR   Ensembl; ENST00000502527.2; ENSP00000421362.2; ENSG00000038427.16. [P13611-4]
DR   GeneID; 1462; -.
DR   KEGG; hsa:1462; -.
DR   MANE-Select; ENST00000265077.8; ENSP00000265077.3; NM_004385.5; NP_004376.2.
DR   UCSC; uc003kii.4; human. [P13611-1]
DR   CTD; 1462; -.
DR   DisGeNET; 1462; -.
DR   GeneCards; VCAN; -.
DR   GeneReviews; VCAN; -.
DR   HGNC; HGNC:2464; VCAN.
DR   HPA; ENSG00000038427; Tissue enhanced (lymphoid tissue, placenta).
DR   MalaCards; VCAN; -.
DR   MIM; 118661; gene.
DR   MIM; 143200; phenotype.
DR   neXtProt; NX_P13611; -.
DR   OpenTargets; ENSG00000038427; -.
DR   Orphanet; 898; Wagner disease.
DR   PharmGKB; PA162408788; -.
DR   VEuPathDB; HostDB:ENSG00000038427; -.
DR   eggNOG; ENOG502QRBE; Eukaryota.
DR   GeneTree; ENSGT00940000156102; -.
DR   HOGENOM; CLU_000303_1_1_1; -.
DR   InParanoid; P13611; -.
DR   OMA; GDSTDNF; -.
DR   PhylomeDB; P13611; -.
DR   TreeFam; TF332134; -.
DR   PathwayCommons; P13611; -.
DR   Reactome; R-HSA-1971475; A tetrasaccharide linker sequence is required for GAG synthesis.
DR   Reactome; R-HSA-2022870; Chondroitin sulfate biosynthesis.
DR   Reactome; R-HSA-2022923; Dermatan sulfate biosynthesis.
DR   Reactome; R-HSA-2024101; CS/DS degradation.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-3560783; Defective B4GALT7 causes EDS, progeroid type.
DR   Reactome; R-HSA-3560801; Defective B3GAT3 causes JDSSDHD.
DR   Reactome; R-HSA-3595172; Defective CHST3 causes SEDCJD.
DR   Reactome; R-HSA-3595174; Defective CHST14 causes EDS, musculocontractural type.
DR   Reactome; R-HSA-3595177; Defective CHSY1 causes TPBS.
DR   Reactome; R-HSA-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-HSA-4420332; Defective B3GALT6 causes EDSP2 and SEMDJL1.
DR   Reactome; R-HSA-8957275; Post-translational protein phosphorylation.
DR   SignaLink; P13611; -.
DR   SIGNOR; P13611; -.
DR   BioGRID-ORCS; 1462; 7 hits in 1064 CRISPR screens.
DR   ChiTaRS; VCAN; human.
DR   GeneWiki; Versican; -.
DR   GenomeRNAi; 1462; -.
DR   Pharos; P13611; Tbio.
DR   PRO; PR:P13611; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P13611; protein.
DR   Bgee; ENSG00000038427; Expressed in monocyte and 206 other tissues.
DR   ExpressionAtlas; P13611; baseline and differential.
DR   Genevisible; P13611; HS.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0031012; C:extracellular matrix; IBA:GO_Central.
DR   GO; GO:0005576; C:extracellular region; HDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; HDA:BHF-UCL.
DR   GO; GO:0005796; C:Golgi lumen; TAS:Reactome.
DR   GO; GO:0033165; C:interphotoreceptor matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0001750; C:photoreceptor outer segment; IEA:UniProtKB-SubCell.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW.
DR   GO; GO:0030021; F:extracellular matrix structural constituent conferring compression resistance; ISS:BHF-UCL.
DR   GO; GO:0005539; F:glycosaminoglycan binding; TAS:ProtInc.
DR   GO; GO:0005540; F:hyaluronic acid binding; TAS:ProtInc.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0008037; P:cell recognition; TAS:ProtInc.
DR   GO; GO:0007417; P:central nervous system development; IBA:GO_Central.
DR   GO; GO:0008347; P:glial cell migration; IDA:BHF-UCL.
DR   GO; GO:0001649; P:osteoblast differentiation; HDA:UniProtKB.
DR   GO; GO:0001501; P:skeletal system development; IBA:GO_Central.
DR   CDD; cd00033; CCP; 1.
DR   CDD; cd03588; CLECT_CSPGs; 1.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.10.100.10; -; 3.
DR   InterPro; IPR001304; C-type_lectin-like.
DR   InterPro; IPR016186; C-type_lectin-like/link_sf.
DR   InterPro; IPR018378; C-type_lectin_CS.
DR   InterPro; IPR033987; CSPG_CTLD.
DR   InterPro; IPR016187; CTDL_fold.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR013106; Ig_V-set.
DR   InterPro; IPR000538; Link_dom.
DR   InterPro; IPR035976; Sushi/SCR/CCP_sf.
DR   InterPro; IPR000436; Sushi_SCR_CCP_dom.
DR   Pfam; PF00008; EGF; 2.
DR   Pfam; PF00059; Lectin_C; 1.
DR   Pfam; PF00084; Sushi; 1.
DR   Pfam; PF07686; V-set; 1.
DR   Pfam; PF00193; Xlink; 2.
DR   PRINTS; PR01265; LINKMODULE.
DR   SMART; SM00032; CCP; 1.
DR   SMART; SM00034; CLECT; 1.
DR   SMART; SM00181; EGF; 2.
DR   SMART; SM00179; EGF_CA; 2.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00445; LINK; 2.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   SUPFAM; SSF56436; SSF56436; 3.
DR   SUPFAM; SSF57535; SSF57535; 1.
DR   PROSITE; PS00010; ASX_HYDROXYL; 1.
DR   PROSITE; PS00615; C_TYPE_LECTIN_1; 1.
DR   PROSITE; PS50041; C_TYPE_LECTIN_2; 1.
DR   PROSITE; PS00022; EGF_1; 2.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS50026; EGF_3; 2.
DR   PROSITE; PS01187; EGF_CA; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS01241; LINK_1; 2.
DR   PROSITE; PS50963; LINK_2; 2.
DR   PROSITE; PS50923; SUSHI; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Calcium; Cataract; Cell projection;
KW   Direct protein sequencing; Disulfide bond; EGF-like domain;
KW   Extracellular matrix; Glycoprotein; Hyaluronic acid; Immunoglobulin domain;
KW   Lectin; Phosphoprotein; Proteoglycan; Reference proteome; Repeat; Secreted;
KW   Signal; Sushi.
FT   SIGNAL          1..20
FT                   /evidence="ECO:0000269|PubMed:1429726"
FT   CHAIN           21..3396
FT                   /note="Versican core protein"
FT                   /id="PRO_0000017522"
FT   DOMAIN          21..146
FT                   /note="Ig-like V-type"
FT   DOMAIN          150..245
FT                   /note="Link 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00323"
FT   DOMAIN          251..347
FT                   /note="Link 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00323"
FT   DOMAIN          3089..3125
FT                   /note="EGF-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          3127..3163
FT                   /note="EGF-like 2; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          3176..3290
FT                   /note="C-type lectin"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   DOMAIN          3294..3354
FT                   /note="Sushi"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302"
FT   REGION          348..1335
FT                   /note="GAG-alpha (glucosaminoglycan attachment domain)"
FT   REGION          420..439
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          603..622
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          807..829
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1126..1154
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1277..1316
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1336..3089
FT                   /note="GAG-beta"
FT   REGION          1420..1497
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1510..1539
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1717..1737
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1759..1789
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1962..1994
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2107..2134
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2168..2188
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2371..2396
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2445..2473
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2493..2518
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2598..2617
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2834..2856
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2881..2905
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          3371..3396
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1138..1154
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1435..1453
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1461..1480
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1717..1732
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1963..1994
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2445..2463
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2493..2517
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        3378..3396
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            1428..1429
FT                   /note="Cleavage; by ADAMTS15"
FT                   /evidence="ECO:0000250|UniProtKB:Q62059"
FT   MOD_RES         2116
FT                   /note="Phosphoserine; by FAM20C"
FT                   /evidence="ECO:0000269|PubMed:26091039,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         2608
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62059"
FT   MOD_RES         2617
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   CARBOHYD        57
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        330
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        615
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        782
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        809
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1332
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1398
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1442
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1468
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1663
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1898
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2179
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2272
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2280
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2360
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2385
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2392
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2496
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2628
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2934
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        3067
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        3369
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        3379
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        44..130
FT                   /evidence="ECO:0000250"
FT   DISULFID        172..243
FT                   /evidence="ECO:0000250"
FT   DISULFID        196..217
FT                   /evidence="ECO:0000250"
FT   DISULFID        270..345
FT                   /evidence="ECO:0000250"
FT   DISULFID        294..315
FT                   /evidence="ECO:0000250"
FT   DISULFID        3093..3104
FT                   /evidence="ECO:0000250"
FT   DISULFID        3098..3113
FT                   /evidence="ECO:0000250"
FT   DISULFID        3115..3124
FT                   /evidence="ECO:0000250"
FT   DISULFID        3131..3142
FT                   /evidence="ECO:0000250"
FT   DISULFID        3136..3151
FT                   /evidence="ECO:0000250"
FT   DISULFID        3153..3162
FT                   /evidence="ECO:0000250"
FT   DISULFID        3169..3180
FT                   /evidence="ECO:0000250"
FT   DISULFID        3197..3289
FT                   /evidence="ECO:0000250"
FT   DISULFID        3265..3281
FT                   /evidence="ECO:0000250"
FT   DISULFID        3296..3339
FT                   /evidence="ECO:0000250"
FT   DISULFID        3325..3352
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         348
FT                   /note="P -> R (in isoform V1 and isoform V3)"
FT                   /evidence="ECO:0000303|PubMed:2583089,
FT                   ECO:0000303|PubMed:7876137, ECO:0000303|PubMed:7921538"
FT                   /id="VSP_003082"
FT   VAR_SEQ         349..3089
FT                   /note="Missing (in isoform V3)"
FT                   /evidence="ECO:0000303|PubMed:7876137"
FT                   /id="VSP_003085"
FT   VAR_SEQ         349..1335
FT                   /note="Missing (in isoform V1)"
FT                   /evidence="ECO:0000303|PubMed:2583089,
FT                   ECO:0000303|PubMed:7921538"
FT                   /id="VSP_003083"
FT   VAR_SEQ         1336..3089
FT                   /note="Missing (in isoform V2)"
FT                   /evidence="ECO:0000303|PubMed:7806529"
FT                   /id="VSP_003084"
FT   VAR_SEQ         3355..3396
FT                   /note="PSAYQRTYSMKYFKNSSSAKDNSINTSKHDHRWSRRWQESRR -> RKWSFR
FT                   KNGLPCYNNY (in isoform Vint)"
FT                   /evidence="ECO:0000303|PubMed:10397680"
FT                   /id="VSP_003086"
FT   VARIANT         300
FT                   /note="S -> L (in dbSNP:rs2652098)"
FT                   /id="VAR_021958"
FT   VARIANT         428
FT                   /note="G -> D (in dbSNP:rs2287926)"
FT                   /id="VAR_020214"
FT   VARIANT         1516
FT                   /note="K -> R (in dbSNP:rs309559)"
FT                   /id="VAR_021959"
FT   VARIANT         1826
FT                   /note="R -> H (in dbSNP:rs188703)"
FT                   /id="VAR_031632"
FT   VARIANT         2301
FT                   /note="F -> Y (in dbSNP:rs160278)"
FT                   /id="VAR_020215"
FT   VARIANT         2315
FT                   /note="V -> L (in dbSNP:rs3734094)"
FT                   /id="VAR_020216"
FT   VARIANT         2937
FT                   /note="D -> Y (in dbSNP:rs160277)"
FT                   /id="VAR_021960"
FT   VARIANT         3011
FT                   /note="N -> K (in dbSNP:rs16900532)"
FT                   /id="VAR_031633"
FT   CONFLICT        88
FT                   /note="N -> D (in Ref. 10; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        260
FT                   /note="K -> I (in Ref. 10; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        274
FT                   /note="D -> A (in Ref. 4; BAA06801)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        284
FT                   /note="Q -> G (in Ref. 10; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2709..2713
FT                   /note="IKAEA -> EFREV (in Ref. 7; AAA36437)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   3396 AA;  372820 MW;  D174A1BBB8304FEC CRC64;
     MFINIKSILW MCSTLIVTHA LHKVKVGKSP PVRGSLSGKV SLPCHFSTMP TLPPSYNTSE
     FLRIKWSKIE VDKNGKDLKE TTVLVAQNGN IKIGQDYKGR VSVPTHPEAV GDASLTVVKL
     LASDAGLYRC DVMYGIEDTQ DTVSLTVDGV VFHYRAATSR YTLNFEAAQK ACLDVGAVIA
     TPEQLFAAYE DGFEQCDAGW LADQTVRYPI RAPRVGCYGD KMGKAGVRTY GFRSPQETYD
     VYCYVDHLDG DVFHLTVPSK FTFEEAAKEC ENQDARLATV GELQAAWRNG FDQCDYGWLS
     DASVRHPVTV ARAQCGGGLL GVRTLYRFEN QTGFPPPDSR FDAYCFKPKE ATTIDLSILA
     ETASPSLSKE PQMVSDRTTP IIPLVDELPV IPTEFPPVGN IVSFEQKATV QPQAITDSLA
     TKLPTPTGST KKPWDMDDYS PSASGPLGKL DISEIKEEVL QSTTGVSHYA TDSWDGVVED
     KQTQESVTQI EQIEVGPLVT SMEILKHIPS KEFPVTETPL VTARMILESK TEKKMVSTVS
     ELVTTGHYGF TLGEEDDEDR TLTVGSDEST LIFDQIPEVI TVSKTSEDTI HTHLEDLESV
     SASTTVSPLI MPDNNGSSMD DWEERQTSGR ITEEFLGKYL STTPFPSQHR TEIELFPYSG
     DKILVEGIST VIYPSLQTEM THRRERTETL IPEMRTDTYT DEIQEEITKS PFMGKTEEEV
     FSGMKLSTSL SEPIHVTESS VEMTKSFDFP TLITKLSAEP TEVRDMEEDF TATPGTTKYD
     ENITTVLLAH GTLSVEAATV SKWSWDEDNT TSKPLESTEP SASSKLPPAL LTTVGMNGKD
     KDIPSFTEDG ADEFTLIPDS TQKQLEEVTD EDIAAHGKFT IRFQPTTSTG IAEKSTLRDS
     TTEEKVPPIT STEGQVYATM EGSALGEVED VDLSKPVSTV PQFAHTSEVE GLAFVSYSST
     QEPTTYVDSS HTIPLSVIPK TDWGVLVPSV PSEDEVLGEP SQDILVIDQT RLEATISPET
     MRTTKITEGT TQEEFPWKEQ TAEKPVPALS STAWTPKEAV TPLDEQEGDG SAYTVSEDEL
     LTGSERVPVL ETTPVGKIDH SVSYPPGAVT EHKVKTDEVV TLTPRIGPKV SLSPGPEQKY
     ETEGSSTTGF TSSLSPFSTH ITQLMEETTT EKTSLEDIDL GSGLFEKPKA TELIEFSTIK
     VTVPSDITTA FSSVDRLHTT SAFKPSSAIT KKPPLIDREP GEETTSDMVI IGESTSHVPP
     TTLEDIVAKE TETDIDREYF TTSSPPATQP TRPPTVEDKE AFGPQALSTP QPPASTKFHP
     DINVYIIEVR ENKTGRMSDL SVIGHPIDSE SKEDEPCSEE TDPVHDLMAE ILPEFPDIIE
     IDLYHSEENE EEEEECANAT DVTTTPSVQY INGKHLVTTV PKDPEAAEAR RGQFESVAPS
     QNFSDSSESD THPFVIAKTE LSTAVQPNES TETTESLEVT WKPETYPETS EHFSGGEPDV
     FPTVPFHEEF ESGTAKKGAE SVTERDTEVG HQAHEHTEPV SLFPEESSGE IAIDQESQKI
     AFARATEVTF GEEVEKSTSV TYTPTIVPSS ASAYVSEEEA VTLIGNPWPD DLLSTKESWV
     EATPRQVVEL SGSSSIPITE GSGEAEEDED TMFTMVTDLS QRNTTDTLIT LDTSRIITES
     FFEVPATTIY PVSEQPSAKV VPTKFVSETD TSEWISSTTV EEKKRKEEEG TTGTASTFEV
     YSSTQRSDQL ILPFELESPN VATSSDSGTR KSFMSLTTPT QSEREMTDST PVFTETNTLE
     NLGAQTTEHS SIHQPGVQEG LTTLPRSPAS VFMEQGSGEA AADPETTTVS SFSLNVEYAI
     QAEKEVAGTL SPHVETTFST EPTGLVLSTV MDRVVAENIT QTSREIVISE RLGEPNYGAE
     IRGFSTGFPL EEDFSGDFRE YSTVSHPIAK EETVMMEGSG DAAFRDTQTS PSTVPTSVHI
     SHISDSEGPS STMVSTSAFP WEEFTSSAEG SGEQLVTVSS SVVPVLPSAV QKFSGTASSI
     IDEGLGEVGT VNEIDRRSTI LPTAEVEGTK APVEKEEVKV SGTVSTNFPQ TIEPAKLWSR
     QEVNPVRQEI ESETTSEEQI QEEKSFESPQ NSPATEQTIF DSQTFTETEL KTTDYSVLTT
     KKTYSDDKEM KEEDTSLVNM STPDPDANGL ESYTTLPEAT EKSHFFLATA LVTESIPAEH
     VVTDSPIKKE ESTKHFPKGM RPTIQESDTE LLFSGLGSGE EVLPTLPTES VNFTEVEQIN
     NTLYPHTSQV ESTSSDKIED FNRMENVAKE VGPLVSQTDI FEGSGSVTST TLIEILSDTG
     AEGPTVAPLP FSTDIGHPQN QTVRWAEEIQ TSRPQTITEQ DSNKNSSTAE INETTTSSTD
     FLARAYGFEM AKEFVTSAPK PSDLYYEPSG EGSGEVDIVD SFHTSATTQA TRQESSTTFV
     SDGSLEKHPE VPSAKAVTAD GFPTVSVMLP LHSEQNKSSP DPTSTLSNTV SYERSTDGSF
     QDRFREFEDS TLKPNRKKPT ENIIIDLDKE DKDLILTITE STILEILPEL TSDKNTIIDI
     DHTKPVYEDI LGMQTDIDTE VPSEPHDSND ESNDDSTQVQ EIYEAAVNLS LTEETFEGSA
     DVLASYTQAT HDESMTYEDR SQLDHMGFHF TTGIPAPSTE TELDVLLPTA TSLPIPRKSA
     TVIPEIEGIK AEAKALDDMF ESSTLSDGQA IADQSEIIPT LGQFERTQEE YEDKKHAGPS
     FQPEFSSGAE EALVDHTPYL SIATTHLMDQ SVTEVPDVME GSNPPYYTDT TLAVSTFAKL
     SSQTPSSPLT IYSGSEASGH TEIPQPSALP GIDVGSSVMS PQDSFKEIHV NIEATFKPSS
     EEYLHITEPP SLSPDTKLEP SEDDGKPELL EEMEASPTEL IAVEGTEILQ DFQNKTDGQV
     SGEAIKMFPT IKTPEAGTVI TTADEIELEG ATQWPHSTSA SATYGVEAGV VPWLSPQTSE
     RPTLSSSPEI NPETQAALIR GQDSTIAASE QQVAARILDS NDQATVNPVE FNTEVATPPF
     SLLETSNETD FLIGINEESV EGTAIYLPGP DRCKMNPCLN GGTCYPTETS YVCTCVPGYS
     GDQCELDFDE CHSNPCRNGA TCVDGFNTFR CLCLPSYVGA LCEQDTETCD YGWHKFQGQC
     YKYFAHRRTW DAAERECRLQ GAHLTSILSH EEQMFVNRVG HDYQWIGLND KMFEHDFRWT
     DGSTLQYENW RPNQPDSFFS AGEDCVVIIW HENGQWNDVP CNYHLTYTCK KGTVACGQPP
     VVENAKTFGK MKPRYEINSL IRYHCKDGFI QRHLPTIRCL GNGRWAIPKI TCMNPSAYQR
     TYSMKYFKNS SSAKDNSINT SKHDHRWSRR WQESRR
//
